Literature DB >> 20144424

Overnight closed-loop insulin delivery with model predictive control: assessment of hypoglycemia and hyperglycemia risk using simulation studies.

Malgorzata E Wilinska1, Erwin S Budiman, Marc B Taub, Daniela Elleri, Janet M Allen, Carlo L Acerini, David B Dunger, Roman Hovorka.   

Abstract

BACKGROUND: Hypoglycemia and hyperglycemia during closed-loop insulin delivery based on subcutaneous (SC) glucose sensing may arise due to (1) overdosing and underdosing of insulin by control algorithm and (2) difference between plasma glucose (PG) and sensor glucose, which may be transient (kinetics origin and sensor artifacts) or persistent (calibration error [CE]). Using in silico testing, we assessed hypoglycemia and hyperglycemia incidence during over-night closed loop. Additionally, a comparison was made against incidence observed experimentally during open-loop single-night in-clinic studies in young people with type 1 diabetes mellitus (T1DM) treated by continuous SC insulin infusion.
METHODS: Simulation environment comprising 18 virtual subjects with T1DM was used to simulate overnight closed-loop study with a model predictive control (MPC) algorithm. A 15 h experiment started at 17:00 and ended at 08:00 the next day. Closed loop commenced at 21:00 and continued for 11 h. At 18:00, protocol included meal (50 g carbohydrates) accompanied by prandial insulin. The MPC algorithm advised on insulin infusion every 15 min. Sensor glucose was obtained by combining model-calculated noise-free interstitial glucose with experimentally derived transient and persistent sensor artifacts associated with FreeStyle Navigator (FSN). Transient artifacts were obtained from FSN sensor pairs worn by 58 subjects with T1DM over 194 nighttime periods. Persistent difference due to FSN CE was quantified from 585 FSN sensor insertions, yielding 1421 calibration sessions from 248 subjects with diabetes.
RESULTS: Episodes of severe (PG < or = 36 mg/dl) and significant (PG < or = 45 mg/dl) hypoglycemia and significant hyperglycemia (PG > or = 300 mg/dl) were extracted from 18,000 simulated closed-loop nights. Severe hypoglycemia was not observed when FSN CE was less than 45%. Hypoglycemia and hyperglycemia incidence during open loop was assessed from 21 overnight studies in 17 young subjects with T1DM (8 males; 13.5 +/- 3.6 years of age; body mass index 21.0 +/- 4.0 kg/m2; duration diabetes 6.4 +/- 4.1 years; hemoglobin A1c 8.5% +/- 1.8%; mean +/- standard deviation) participating in the Artificial Pancreas Project at Cambridge. Severe and significant hypoglycemia during simulated closed loop occurred 0.75 and 17.11 times per 100 person years compared to 1739 and 3479 times per 100 person years during experimental open loop, respectively. Significant hyperglycemia during closed loop and open loop occurred 75 and 15,654 times per 100 person years, respectively.
CONCLUSIONS: The incidence of severe and significant hypoglycemia reduced 2300- and 200-fold, respectively, during stimulated overnight closed loop with MPC compared to that observed during open-loop overnight clinical studies in young subjects with T1DM. Hyperglycemia was 200 times less likely. Overnight closed loop with the FSN and the MPC algorithm is expected to reduce substantially the risk of hypoglycemia and hyperglycemia. 2009 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20144424      PMCID: PMC2769888          DOI: 10.1177/193229680900300514

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  26 in total

Review 1.  Continuous glucose monitoring: roadmap for 21st century diabetes therapy.

Authors:  David C Klonoff
Journal:  Diabetes Care       Date:  2005-05       Impact factor: 19.112

2.  Accuracy of the 5-day FreeStyle Navigator Continuous Glucose Monitoring System: comparison with frequent laboratory reference measurements.

Authors:  Richard L Weinstein; Sherwyn L Schwartz; Ronald L Brazg; Jolyon R Bugler; Thomas A Peyser; Geoffrey V McGarraugh
Journal:  Diabetes Care       Date:  2007-03-02       Impact factor: 19.112

Review 3.  The future of continuous glucose monitoring: closed loop.

Authors:  Roman Hovorka
Journal:  Curr Diabetes Rev       Date:  2008-08

Review 4.  Closed-loop insulin delivery - what lies between where we are and where we are going?

Authors:  Garry M Steil; Kerstin Rebrin
Journal:  Expert Opin Drug Deliv       Date:  2005-03       Impact factor: 6.648

Review 5.  Closing the loop: combining insulin pumps and glucose sensors in children with type 1 diabetes mellitus.

Authors:  Shlomit Shalitin; Moshe Phillip
Journal:  Pediatr Diabetes       Date:  2006-08       Impact factor: 4.866

6.  In silico preclinical trials: methodology and engineering guide to closed-loop control in type 1 diabetes mellitus.

Authors:  Stephen D Patek; B Wayne Bequette; Marc Breton; Bruce A Buckingham; Eyal Dassau; Francis J Doyle; John Lum; Lalo Magni; Howard Zisser
Journal:  J Diabetes Sci Technol       Date:  2009-03-01

7.  Automated feedback control of subcutaneous glucose concentration in diabetic dogs.

Authors:  K Rebrin; U Fischer; T von Woedtke; P Abel; E Brunstein
Journal:  Diabetologia       Date:  1989-08       Impact factor: 10.122

8.  Partitioning glucose distribution/transport, disposal, and endogenous production during IVGTT.

Authors:  Roman Hovorka; Fariba Shojaee-Moradie; Paul V Carroll; Ludovic J Chassin; Ian J Gowrie; Nicola C Jackson; Romulus S Tudor; A Margot Umpleby; Richard H Jones
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-05       Impact factor: 4.310

9.  Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia.

Authors:  J C Pickup; H Keen; J A Parsons; K G Alberti
Journal:  Br Med J       Date:  1978-01-28

10.  Continuous glucose monitoring and intensive treatment of type 1 diabetes.

Authors:  William V Tamborlane; Roy W Beck; Bruce W Bode; Bruce Buckingham; H Peter Chase; Robert Clemons; Rosanna Fiallo-Scharer; Larry A Fox; Lisa K Gilliam; Irl B Hirsch; Elbert S Huang; Craig Kollman; Aaron J Kowalski; Lori Laffel; Jean M Lawrence; Joyce Lee; Nelly Mauras; Michael O'Grady; Katrina J Ruedy; Michael Tansey; Eva Tsalikian; Stuart Weinzimer; Darrell M Wilson; Howard Wolpert; Tim Wysocki; Dongyuan Xing
Journal:  N Engl J Med       Date:  2008-09-08       Impact factor: 91.245

View more
  27 in total

1.  Impact of blood glucose self-monitoring errors on glucose variability, risk for hypoglycemia, and average glucose control in type 1 diabetes: an in silico study.

Authors:  Marc D Breton; Boris P Kovatchev
Journal:  J Diabetes Sci Technol       Date:  2010-05-01

2.  Modeling the error of continuous glucose monitoring sensor data: critical aspects discussed through simulation studies.

Authors:  Andrea Facchinetti; Giovanni Sparacino; Claudio Cobelli
Journal:  J Diabetes Sci Technol       Date:  2010-01-01

3.  Inpatient trial of an artificial pancreas based on multiple model probabilistic predictive control with repeated large unannounced meals.

Authors:  Fraser Cameron; Günter Niemeyer; Darrell M Wilson; B Wayne Bequette; Kari S Benassi; Paula Clinton; Bruce A Buckingham
Journal:  Diabetes Technol Ther       Date:  2014-09-26       Impact factor: 6.118

4.  Modelling the effect of insulin on the disposal of meal-attributable glucose in type 1 diabetes.

Authors:  Fernando García-García; Roman Hovorka; Malgorzata E Wilinska; Daniela Elleri; M Elena Hernando
Journal:  Med Biol Eng Comput       Date:  2016-05-07       Impact factor: 2.602

5.  Stabilized glucagon formulation for bihormonal pump use.

Authors:  Solomon S Steiner; Ming Li; Robert Hauser; Roderike Pohl
Journal:  J Diabetes Sci Technol       Date:  2010-11-01

6.  Progress in development of an artificial pancreas.

Authors:  David C Klonoff; Claudio Cobelli; Boris Kovatchev; Howard C Zisser
Journal:  J Diabetes Sci Technol       Date:  2009-09-01

7.  Evaluating the accuracy and large inaccuracy of two continuous glucose monitoring systems.

Authors:  Lalantha Leelarathna; Marianna Nodale; Janet M Allen; Daniela Elleri; Kavita Kumareswaran; Ahmad Haidar; Karen Caldwell; Malgorzata E Wilinska; Carlo L Acerini; Mark L Evans; Helen R Murphy; David B Dunger; Roman Hovorka
Journal:  Diabetes Technol Ther       Date:  2012-12-20       Impact factor: 6.118

8.  Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.

Authors:  Venkat Sasidhar Renukuntla; Neesha Ramchandani; Jeniece Trast; Martin Cantwell; Rubina A Heptulla
Journal:  J Diabetes Sci Technol       Date:  2014-07-16

9.  Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial.

Authors:  Jeniece Trast Ilkowitz; Ranjitha Katikaneni; Martin Cantwell; Neesha Ramchandani; Rubina A Heptulla
Journal:  J Diabetes Sci Technol       Date:  2016-08-22

10.  Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Suboptimally Controlled Adolescents With Type 1 Diabetes: A 3-Week, Free-Living, Randomized Crossover Trial.

Authors:  Martin Tauschmann; Janet M Allen; Malgorzata E Wilinska; Hood Thabit; Carlo L Acerini; David B Dunger; Roman Hovorka
Journal:  Diabetes Care       Date:  2016-09-09       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.